Regulatory & Legal

With a 2026 launch looming, Nuvalent adds a proven oncology dealmaker to its board, signaling a strategic pivot from R&D to market assault.

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

Micro-cap BSEG racks up awards against giants like Variety, but with a volatile stock and weak fundamentals, can creative success spark a financial turnaround?

A new report shows slow progress on fixing ERs and long-term care, raising questions about government accountability and the real-world cost to Ontarians.

The eyewear giant is moving beyond frames, partnering to design custom chips. A strategic pivot to open-source hardware aims to redefine the market.

A landmark defense contract for 100,000 night-vision devices in Europe signals a major leap in military tech and raises the bar for NATO interoperability.

A new campaign tackles undiagnosed kidney disease. But is it just public health, or a savvy strategy to reshape a multi-billion dollar market?

Kim Thinggaard's return as CEO of Enemærke & Petersen signals a strategic doubling-down on the trust-based partnership model he pioneered.

A regulatory filing reveals a key investor's move as Alkermes' $2.1B bid for Avadel and its blockbuster narcolepsy drug, LUMRYZ, nears its final act.

As federal aid dwindles, a major health system invests in an innovative food network, betting on infrastructure to combat hunger and chronic disease.

A new partnership aims to rapidly upskill the U.S. public sector workforce, providing critical cyber defenses against a surge in AI-powered attacks.

As climate disasters escalate, a major insurer is shifting from payouts to prevention. We decode this signal and its implications for the future of risk.

A $2.4B deal for AI's future. A hedge fund's strategic play. We decode the battle for Alphawave, the company powering the next tech revolution.

A hedge fund's 2.34% derivatives stake in Alphawave IP suggests a major acquisition by Qualcomm, highlighting a high-stakes battle for key chip IP.

A minor share sale by a US giant in a UK tech firm reveals the subtle art of institutional investing and the power of regulatory transparency.

Lightbeam's new NCQA prevalidation isn't just a certificate. It's a strategic move reshaping compliance, patient outcomes, and the health tech market.

The CRA's shift to online-only mail promises efficiency but creates new risks. Are Canadian businesses prepared for the compliance and security challenges?

The 2025 proxy season saw record director support as investors prioritized financials, yet dissent over executive pay signals a new battleground.

Balyasny Asset Management's complex derivative stake in JTC plc reveals the hidden strategies shaping a major takeover and the capital flows funding innovation.

With a new patent, this biotech targets the massive orthopedics market. But can its novel fibroblast therapy overcome steep financial and clinical hurdles?